Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Denagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.76 |
| ▸ | FAP | Q12884 | 8/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13986697 | 0.92 | DPP4 (0.89) | DPP4FAPDPP7DPP8DPP9 | |
| Denagliptin SCHEMBL18815071 | 0.87 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| Denagliptin SCHEMBL2552817 | 0.87 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| Denagliptin SCHEMBL682185 | 0.87 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| Denagliptin SCHEMBL987759 | 0.87 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| Denagliptin SCHEMBL1035624 | 0.87 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| Denagliptin SCHEMBL3151455 | 0.86 | DPP4 (0.98) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL12350113 | 0.78 | DPP4 (0.77) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL5549926 | 0.78 | DPP4 (0.80) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3157260 | 0.77 | DPP4 (0.79) | DPP4FAPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462641-B2 | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | claimed |
| EP-1654226-B1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | claimed |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION | 2007-03-22 | — | — | US | claimed |
| EP-1654226-A1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SmithKline Beecham Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005009956-A1 | (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20260144787-A1 | COMPOSITIONS AND METHODS FOR TREATING STIMULANT-INDUCED AGITATION | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-12640229-B1 | Methods and systems for leveraging links between phenotypic and genotypic data for plants | MONSANTO TECHNOLOGY LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-12390422-B2 | Transdermal drug delivery patch, drug delivery system and drug delivery | Passport Technologies, Inc. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-3453403-B1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-12115179-B2 | Pharmaceutical composition, methods for treating and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-10-15 | — | — | US | disclosed |
| US-20240307403-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2024-09-19 | — | — | US | disclosed |
| US-20230338386-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION | 2007-03-22 | — | — | US | disclosed |
| CN-1852893-A | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORP (US) | 2006-10-25 | — | — | CN | disclosed |
| CN-1852893-A | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORP (US) | 2006-10-25 | — | — | CN | disclosed |
| EP-1654226-A1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SmithKline Beecham Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654226-A1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SmithKline Beecham Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009956-A1 | (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009956-A1 | (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12640229-B1 | Methods and systems for leveraging links between phenotypic and genotypic data for plants | MSL1, MOK, VARS1 | DPP4 4169/4885FAP 4813/4885DPP7 3239/4885 |
| US-20240307403-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 27/4885DPP7 3/4885 |
| US-12115179-B2 | Pharmaceutical composition, methods for treating and uses thereof | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885FAP 497/4885DPP7 4/4885 |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | PFAS, TTR, PNN | DPP4 283/4885FAP 28/4885DPP7 943/4885 |
| US-20260144787-A1 | COMPOSITIONS AND METHODS FOR TREATING STIMULANT-INDUCED AGITATION | OPRM1, CHRM4, DRD2 | DPP4 2943/4885FAP 4588/4885DPP7 4208/4885 |
| US-20230338386-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 27/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.